ESSA Pharma Presents Early Results from Clinical Trial Testing EPI-506 in End-stage Prostate Cancer

ESSA Pharma Presents Early Results from Clinical Trial Testing EPI-506 in End-stage Prostate Cancer
ESSA Pharma‘s small molecule androgen receptor inhibitor, EPI-506 (ralaniten acetate), has shown a favorable safety and tolerability profile among end-stage prostate cancer patients enrolled in a Phase 1/2 trial, as well as promising preliminary efficacy in higher-dose cohorts. Dr. Kim N. Chi, a prostate cancer expert at Vancouver’s BC Cancer Agency, gave a poster presentation at

Knowledge is power when living with prostate cancer.

Get access to the web’s leading Prostate Cancer news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *